The Weekly Litigation News Digest is now live. Subscribe now

Sloan Kettering Institute For Cancer Research competitive analysis

Loading summary...

Explore Sloan Kettering Institute For Cancer Research's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
May 5, 2021Crystalline Forms Of An Androgen Receptor Modulator1
Jul 8, 2020Crystalline Forms Of An Androgen Receptor Modulator2
Apr 18, 2018Crystalline Forms Of An Androgen Receptor Modulator3

Latest PTAB cases involving Sloan Kettering Institute For Cancer Research

Discover the latest PTAB cases involving Sloan Kettering Institute For Cancer Research, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 13, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Sloan Kettering Institute For Cancer Research

IPR2023-00070Oct 18, 2022BLUEBIRD BIOSLOAN KETTERING INSTITUTE FOR CANCER RESEARCHFinal Written Decision
IPR2023-00074Oct 18, 2022BLUEBIRD BIOSLOAN KETTERING INSTITUTE FOR CANCER RESEARCHFinal Written Decision
IPR2015-01719Aug 13, 2015KITE PHARMASLOAN KETTERING INSTITUTE FOR CANCER RESEARCHFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Sloan Kettering Institute For Cancer Research with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH - 6 - 3
BLUEBIRD BIO - 102 -
GENERICS UK214 - - -
KITE PHARMA - 11 -